Хайлтын үр дүнгүүд - David E. Allison

  • 6-н 1 - 6 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

    Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial -н Kelong Han, Jin Jin, Mauricio Maia, John Lowe, Martina Sersch, David E. Allison

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Population pharmacokinetics of bevacizumab in cancer patients with external validation

    Population pharmacokinetics of bevacizumab in cancer patients with external validation -н Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie Gosselin, Sandhya Girish, David E. Allison, Jin Jin

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

    Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer -н David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Y. Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey, Gwen Fyfe

    Хэвлэсэн 2005
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy

    Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progress... -н David B. Agus, Christopher J. Sweeney, Michael J. Morris, David S. Mendelson, Douglas G. McNeel, Frederick R. Ahmann, Jin Wang, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, Michael W. Kattan, Howard I. Scher

    Хэвлэсэн 2007
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Charge variants in IgG1

    Charge variants in IgG1 -н Leslie A. Khawli, Sirj Goswami, Ryan Hutchinson, Zephania W. Kwong, Jihong Yang, Xiangdan Wang, Zhenling Yao, Alavattam Sreedhara, Tony Cano, Devin B. Tesar, Ihsan Nijem, David E. Allison, Pin Yee Wong, Yung‐Hsiang Kao, Cynthia Quan, Amita Joshi, Reed J. Harris, Paul A. Motchnik

    Хэвлэсэн 2010
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

    Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status -н Michael S. Gordon, Daniela Matei, Carol Aghajanian, Ursula A. Matulonis, Molly Brewer, Gini F. Fleming, John D. Hainsworth, Agustin A. García, Mark D. Pegram, Russell J. Schilder, David E. Cohn, Lynda D. Roman, Mika K. Derynck, Kimmie Ng, Benjamin Lyons, David E. Allison, David A. Eberhard, Thinh Q. Pham, Randall C. Dere, Beth Y. Karlan

    Хэвлэсэн 2006
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: